RSWM
QNCX icon

Robertson Stephens Wealth Management’s Quince Therapeutics QNCX Stock Holding History

Robertson Stephens Wealth Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-135
Closed -$167K – 409
2022
Q1 		$167K Sell
135
-71
-34% -$96.6K 0.01% 375
2021
Q4 		$519K Buy
206
+107
+108% +$653K 0.04% 252
2021
Q3 		$1.81M Sell
99
-41
-29% -$652K 0.2% 77
2021
Q2 		$1.48M Buy
140
+21
+18% +$176K 0.18% 92
2021
Q1 		$859K Buy
119
+55
+86% +$396K 0.14% 116
2020
Q4 		$353K Buy
+64
New +$567K 0.07% 170

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Robertson Stephens Wealth Management's QNCX Position: Q2 2022 in Review

Robertson Stephens Wealth Management sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 135 shares — an estimated $167K sold.

Robertson Stephens Wealth Management first reported a position in QNCX in Q4 2020 and held it in 6 quarters. The position peaked at $1.81M in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • Robertson Stephens Wealth Management reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Robertson Stephens Wealth Management sold 135 Quince Therapeutics shares in Q2 2022, an estimated $167K.
  • Robertson Stephens Wealth Management first reported a position in Quince Therapeutics in Q4 2020 and held it in 6 quarters.
  • Robertson Stephens Wealth Management's Quince Therapeutics position peaked at $1.81M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Robertson Stephens Wealth Management's 13F filing for Q2 2022, filed 12 Aug 2022.